Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21374119 | 1.00 | ALDH1A1 (0.38) | ALDH1A1GRIK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28231406 | 0.88 | THRB (0.35) | ALDH1A1GRIK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL910640 | 0.88 | THRB (0.40) | ALDH1A1GRIK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18933137 | 0.85 | HTT (0.35) | ALDH1A1GRIK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5432682 | 0.85 | GRIK1 (0.33) | ALDH1A1GRIK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4327877 | 0.81 | — | — | |
| SCHEMBL2497497 | 0.81 | — | — | |
| SCHEMBL20308918 | 0.81 | SPHK1 (0.47) | ALDH1A1SPHK1CYP2D6LMNAGMNN | |
| SCHEMBL16153750 | 0.80 | TSHR (0.38) | GRIK1SLC1A3SLC1A2SLC1A1GRIK2 | |
| SCHEMBL3096192 | 0.80 | TSHR (0.38) | GRIK1SLC1A3SLC1A2SLC1A1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003034989-A3 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARM INC (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | DNPEP, ASPH, CTSC | ALDH1A1 999/4885GRIK1 2821/4885SLC1A3 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.